SCHEMBL3003136

SCHEMBL3003136

CCOC(=O)N1CCc2ccsc2C(=O)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.46
NOS1 P29475 1/20 0.46
NOS2 P35228 1/20 0.46
ALDH1A1 P00352 4/20 0.44
PRMT5 O14744 2/20 0.44
WDR77 Q9BQA1 2/20 0.44
SMN1; SMN2 Q16637 5/20 0.43
HSD17B10 Q99714 2/20 0.43
LMNA P02545 3/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
PKM P14618 1/20 0.41
PABPC1 P11940 1/20 0.41
ATM Q13315 1/20 0.41
RXFP1 Q9HBX9 2/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 1/20 0.41
ALOX12 P18054 1/20 0.41
CASP1 P29466 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1425227 0.91 NOS3 (0.46) NOS3NOS1NOS2ALDH1A1PRMT5
SCHEMBL2992630 0.85 PRMT5 (0.43) NOS3NOS1NOS2ALDH1A1PRMT5
SCHEMBL985894 0.81 NOS3 (0.44) NOS3NOS1NOS2ALDH1A1PRMT5
SCHEMBL982355 0.80 SMN1; SMN2 (0.50) NOS3NOS1NOS2ALDH1A1PRMT5
SCHEMBL1425864 0.78 KDM4E (0.46) NOS3NOS1NOS2ALDH1A1SMN1; SMN2
SCHEMBL1425321 0.77 PRMT5 (0.49) NOS3NOS1NOS2ALDH1A1PRMT5
SCHEMBL1425282 0.77 PRMT5 (0.47) NOS3NOS1NOS2ALDH1A1PRMT5
SCHEMBL16268868 0.74 ALDH1A1 (0.64) ALDH1A1PRMT5WDR77SMN1; SMN2NPC1
SCHEMBL2999822 0.74 SMN1; SMN2 (0.41) ALDH1A1PRMT5WDR77SMN1; SMN2HSD17B10
SCHEMBL2995712 0.74 GRM5 (0.43) NOS3NOS1NOS2ALDH1A1PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778243-B1 SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS ATHERSYS INC (US) 2012-10-31 EP disclosed
EP-1778243-B1 SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS ATHERSYS INC (US) 2012-10-31 EP disclosed
US-20100190772-A1 Substituted Azepine Derivatives As Serotonin Receptor Modulators BENNANI YOUSSEF L 2010-07-29 US disclosed
US-20100190772-A1 Substituted Azepine Derivatives As Serotonin Receptor Modulators BENNANI YOUSSEF L 2010-07-29 US disclosed
US-7718647-B2 Substituted azepine derivatives as serotonin receptor modulators ATHERSYS, INC. (US) 2010-05-18 US disclosed
US-7718647-B2 Substituted azepine derivatives as serotonin receptor modulators ATHERSYS, INC. (US) 2010-05-18 US disclosed
US-7718647-B2 Substituted azepine derivatives as serotonin receptor modulators ATHERSYS, INC. (US) 2010-05-18 US disclosed
WO-2008135526-A1 CARBOXYLIC ACID AMIDES AS FACTOR XA INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-11-13 WO disclosed
US-20060003990-A1 Substituted azepine derivatives as serotonin receptor modulators ATHERSYS, INC. 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060003990-A1 Substituted azepine derivatives as serotonin receptor modulators HTR5A, HTR4, HTR7 NOS3 1620/4885NOS1 2166/4885NOS2 2218/4885
US-20100190772-A1 Substituted Azepine Derivatives As Serotonin Receptor Modulators HTR5A, HTR4, HTR2C NOS3 1546/4885NOS1 2048/4885NOS2 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.